Biomarker-informed CSF proteomics reveals ENPP2-LPA lipid signaling associated with Alzheimer's disease

10 Jul 20264 min read0 viewsVerified Feed

GIST (Key Takeaways)

Background: Alzheimer's disease (AD) involves complex molecular alterations in the cerebrospinal fluid (CSF) proteome, yet the links between these protein changes and hallmark AD pathology remain incompletely defined. We investigated the relationship between the CSF proteome with CSF biomarkers of Alzheimer's disease (AD). Methods: CSF was collected in 500 individuals of non-Hispanic white, African Americans, and Caribbean Hispanic individuals.
CSF biomarkers of AD were measured including P-tau181, A{beta}40, A{beta}42, total-tau, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP). CSF was depleted of abundant proteins followed by precipitation, cysteine reduction/alkylation, and proteolytic cleavage by trypsin. Peptides were measured using a Q-Exactive HF mass spectrometer (Thermo Scientific).
Association of individual and co-abundant modules of proteins were tested using elevated CSF P-tau181 and reduced A{beta}42/A{beta}40 to confirm the diagnosis of AD. We validated results in CSF from 397 participants in the Accelerated Medicine Partnership-Alzheimer's Disease cohort. Associated proteins were functionally validated in postmortem human brains and zebrafish.
Results: We detected 1030 proteins, yielding an overall data completeness value of 97%.